Frozen gelling preparation
The frozen gel preparation addresses the challenge of using frozen cell suspensions by enabling direct transplantation and tissue healing without specialized equipment, maintaining therapeutic efficacy and gene expression stability.
Patent Information
- Application Number
- JP2024076385
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-09
- Publication Date
- 2024-12-05
AI Technical Summary
Existing frozen cell suspensions require specialized equipment like centrifuges for thawing and washing, and complex procedures for transplantation, making them difficult to use in non-university medical settings.
A frozen gel preparation is developed by embedding mesenchymal cells in a gel, allowing for direct transplantation after thawing without the need for centrifuges or special techniques, using mesenchymal cells derived from various tissues and potentially activated for enhanced healing properties.
The frozen gel preparation can be used immediately after thawing, eliminating the need for specialized equipment and procedures, facilitating easy transportation and effective tissue healing without gene expression differences from conventional methods.
Smart Images

Figure 2024169333000002 
Figure 2024169333000003 
Figure 2024169333000004
Abstract
Description
[Technical field]
[0001] The present invention relates to a cell preparation. In particular, the present invention relates to a cryogelation preparation comprising mesenchymal cells. [Background technology]
[0002] Cells used for transplantation or tissue healing are sometimes transported to medical institutions in the form of frozen cell suspensions. Various ideas for cell freezing methods have been reported (see, for example, Patent Document 1, etc.). However, with normal frozen cell suspensions, equipment such as a centrifuge is required for thawing and washing, and the equipment also needs to be approved as a medical device. Many medical institutions do not have equipment such as centrifuges. Furthermore, transplantation or application of thawed cells requires special procedures such as resuspension of the cells. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] JP 2016-073207 A Summary of the Invention [Problem to be solved by the invention]
[0004] There has been a demand for frozen cell preparations that can be used immediately after freezing, that do not require special equipment such as a centrifuge for thawing and washing, and that do not require special procedures for transplantation or application. [Means for solving the problem]
[0005] The present inventors have conducted extensive research to solve the above problems, and have discovered that the above problems can be solved by a frozen gelation preparation produced by freezing a gel in which mesenchymal cells are embedded, thereby completing the present invention.
[0006] That is, the present invention provides the following: (1) A frozen gel preparation containing mesenchymal cells. (2) The frozen gelation preparation described in (1), wherein the mesenchymal cells are derived from adipose tissue. (3) The frozen gelation preparation according to (1), wherein the mesenchymal cells are derived from pluripotent stem cells. (4) The frozen gelation preparation according to (1), wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs), adipose tissue-derived cells (ASCs), bone marrow-derived stem cells (BSCs), umbilical cord-derived stem cells, dental pulp-derived stem cells, placenta-derived stem cells, cartilage-derived stem cells, or pluripotent stem cell-derived mesenchymal stem cells. (5) The frozen gelation preparation according to (1), wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs). (6) The frozen gelation preparation according to any one of (1) to (5), wherein the mesenchymal cells are activated. (7) The cryogelation preparation according to any one of (1) to (6), which is for use in tissue healing. (8) The cryogelling preparation according to any one of (1) to (7), which is for dental use. (9) A method for producing a frozen gelling agent, comprising embedding mesenchymal cells in a gel and freezing the gel. (10) The method described in (9), wherein the mesenchymal cells are derived from adipose tissue. (11) The method described in (9), wherein the mesenchymal cells are derived from pluripotent stem cells. (12) The method according to (9), wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs), adipose tissue-derived cells (ASCs), bone marrow-derived stem cells (BSCs), umbilical cord-derived stem cells, dental pulp-derived stem cells, placenta-derived stem cells, cartilage-derived stem cells, or pluripotent stem cell-derived mesenchymal stem cells. (13) The method described in (9), wherein the mesenchymal cells are ADMSCs. (14) The method according to any one of (9) to (13), wherein the mesenchymal cells are activated. Effect of the Invention
[0007] The frozen gelling preparation of the present invention can be used immediately after thawing, does not require special equipment such as a centrifuge for thawing and washing, and does not require special procedures for transplantation or application. The frozen gelling preparation of the present invention is not obtained by freezing cells as they are, but by embedding cells in a gel and then freezing them, which enables the procedure of transplanting the frozen gel as it is by simply thawing the frozen gel at the medical site. In addition, the frozen gelling preparation of the present invention has the advantage of being easy to transport because it can be transported in a frozen storage state. [Brief description of the drawings]
[0008] [Figure 1] The three images to the left of the dashed line in Figure 1 are alizarin red stained images of human ADMSCs not activated with IL-1β, and the three images to the right of the dashed line in Figure 1 are alizarin red stained images of human ADMSCs activated with IL-1β. [Diagram 2] Figure 2 shows CT images of the transplantation area in a beagle dog two-wall bone defect model. The left image shows the area where a gelling formulation containing human ADMSCs not activated with IL-1β was transplanted, and the right image shows the area where a gelling formulation containing human ADMSCs activated with IL-1β was transplanted. The area of new bone is highlighted in white. [Diagram 3] Figure 3 shows the mean (mm3) and standard deviation (control, left bar) of new bone mass in the group transplanted with a gelling formulation containing human ADMSCs not activated with IL-1β, and the mean (mm3) and standard deviation (test, right bar) of new bone mass in the group transplanted with a gelling formulation containing human ADMSCs activated with IL-1β in a beagle dog two-wall bone defect model. [Figure 4] Figure 4 shows section images of the transplanted area in a beagle dog two-wall bone defect model. The left image shows a section obtained from an animal transplanted with a gelling formulation containing human ADMSCs not activated with IL-1β, and the right image shows a section obtained from an animal transplanted with a gelling formulation containing human ADMSCs activated with IL-1β. The area of new bone is surrounded by a dashed line. The scale bar is 1000 μm. [Diagram 5]5 is a diagram showing the correlation between gene expression in cell A and gene expression in cell B after 24, 48, 72, and 96 hours of culture. The horizontal axis represents the amount of mRNA expression in cell A, and the vertical axis represents the amount of mRNA expression in cell B. [Figure 6] 6 is a diagram showing the correlation between the expression of eight genes (CSF2, CSF3, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, and IL-1β genes) in cells A and B after 96 hours of culture. The horizontal axis indicates the mRNA expression level of cell A, and the vertical axis indicates the mRNA expression level of cell B. [Figure 7] FIG. 1 shows the correlation between the expression of eight genes (CSF2, CSF3, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, and IL-1β genes) after 24 and 96 hours of culture in cell A. The horizontal axis shows the mRNA expression level after 24 hours of culture, and the vertical axis shows the mRNA expression level after 96 hours of culture. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] In one aspect, the present invention provides a frozen gelation preparation comprising mesenchymal cells.
[0010] The frozen gel preparation is prepared by freezing a gel in which mesenchymal cells are embedded.
[0011] When performing cell transplants for tissue healing, the conventional wisdom has been to freeze the cells, thaw and wash the frozen cells at the medical site, embed them in a gel, and transplant them immediately after embedding (conventional method). However, a centrifuge is required to wash the cells, and the centrifuge itself must obtain medical device approval, making it difficult to provide this medical treatment unless it is a university hospital or the like.
[0012] In contrast, the frozen gelling preparation of the present invention enables the procedure of transplantation as is by simply thawing the frozen gel at the medical site. Therefore, when the frozen gelling preparation of the present invention is used, the transplantation procedure is simple, and since there is no need to obtain medical device approval for the centrifuge, transplantation can be performed even in small-scale clinics. Moreover, the gene expression of the cells in the frozen gelling preparation of the present invention is no different from the gene expression of the cells for transplantation used in conventional methods, and the tissue healing effect can be exerted for a long time after transplantation.
[0013] Mesenchymal cells are known and can be isolated from mesenchymal tissues, such as adipose tissue, bone marrow, umbilical cord, dental pulp, bone marrow, etc. They can also be derived from pluripotent stem cells, etc. Methods for isolating mesenchymal cells are also known. Examples of mesenchymal cells include, but are not limited to, mesenchymal stem cells (MSCs) such as adipose tissue-derived stem cells (ADMSCs), adipose tissue-derived cells (ASCs), bone marrow-derived stem cells (BSCs), umbilical cord-derived stem cells, dental pulp-derived stem cells, placenta-derived stem cells, and cartilage-derived stem cells, as well as pluripotent stem cell-derived mesenchymal stem cells. Any mesenchymal cell can be used in the frozen gelation preparation of the present invention.
[0014] The mesenchymal cells may be commercially available or may be provided by institutions such as the American Type Culture Collection (ATCC) (USA) and JCRB (Japan). Alternatively, the mesenchymal cells may be obtained from mesenchymal tissue. Means and methods for obtaining mesenchymal cells from mesenchymal tissue are known. For the method of obtaining adipose tissue-derived mesenchymal stem cells (ADMSCs), for example, H. Okura et al., Tissue Engineering Part C: Methods Vol, 16, No. 4 (Published Online: 18 Dec 2009|https: / / doi.org / 10.1089 / ten.tec.2009.0208) can be referred to.
[0015] The mesenchymal cells may be derived from the subject to be transplanted or applied, or may be derived from another subject. The subject animal is typically a human, but is not particularly limited, and may be a non-human animal, such as a pet animal such as a dog or a cat.
[0016] The mesenchymal cells embedded in the gel may be either non-activated or activated. Factors that activate mesenchymal cells include inflammatory cytokines, inflammatory cytokine-inducing polypeptides, growth factors, interferons, lipopolysaccharides, and the like. Preferred factors include, but are not limited to, interferon-β (IFN-β), interferon gamma (IFNγ), interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-17A (IL-17A), tumor necrosis factor alpha (TNFα), tumor necrosis factor beta (TNFβ), type I interferon (INF-I), transforming growth factor β (TGFβ), lipopolysaccharides, and the like. Examples of factors that activate mesenchymal cells include IL-1α or IL-1β.
[0017] Activation of mesenchymal cells with an activating factor can be carried out by contacting cells with the activating factor by a known method. Typically, mesenchymal cells can be activated by incubating cells in a medium containing the activating factor. The concentration of the activating factor is not particularly limited and can be determined appropriately. The concentration of the activating factor may be, for example, 5 pg / mL to 100 mg / mL, depending on the type of activating factor and the type of cell. Those skilled in the art can select an appropriate medium depending on the type of cell. The medium may be, for example, DMEM, DMEM / F12, MEM, etc. The incubation temperature and time are also not particularly limited and can be determined appropriately. The incubation temperature may be, for example, 30°C to 38°C. The incubation time may be, for example, 6 hours to 168 hours.
[0018] Any mesenchymal cell may be activated. For example, ASC may be activated, or ADMSC may be activated. Activated mesenchymal cells have the characteristics of having a higher tissue healing ability and a stronger anti-inflammatory effect than non-activated mesenchymal cells. In addition, activated mesenchymal cells express and produce more factors involved in tissue healing than non-activated mesenchymal cells. Such factors include, but are not limited to, adiponectin, HGF, CSF2 (GM-CSF), CSF3 (G-CSF), LIF, factors of the MMP family, factors of the FGF family, factors of the ADAM family, factors of the angiopoietin-like protein family, pleiotrophin, factors of the R-spondin family, and factors of the VEGF family. The increase in expression or production of the above factors may be, for example, 10 times or more, preferably 30 times or more, more preferably 50 times or more, and even more preferably 100 times or more, compared to non-activated cells.
[0019] The type of gel material is not particularly limited, but it is preferable that the gel material is non-toxic to the cells to be embedded or to the subject to be transplanted or applied. In addition, it is preferable that the gel material be capable of becoming a gel at room temperature or body temperature. Examples of such gel materials include, but are not limited to, fibrin, agarose, alginic acid, carrageenan, gelatin, collagen, fibronectin, elastin, laminin, hydroxypropyl cellulose, etc.
[0020] The embedding of cells in a gel may be performed by embedding the cells in a gel that has already been formed, or by adding the cells to a suspension of a gel material and then gelling the suspension containing the cells. Means for gelling a gel material are known and can be selected depending on the gel material. For example, known means include the addition of a crosslinking agent (such as calcium), fibrin gel, and temperature change.
[0021] The number of cells to be embedded can be appropriately selected by those skilled in the art, for example, 1 x 10 cells per 1 mL of gel. 4 ~1x10 8 It may be one piece.
[0022] The size, shape, and hardness of the gel can be appropriately selected by those skilled in the art depending on the type and size of the transplantation site, the type and amount of cells to be embedded, etc. A preferred hardness of the gel is such that the cells do not flow out and can be grasped with tweezers or the like.
[0023] The gel preferably contains a cryoprotectant. Cryoprotectants are known, such as, but not limited to, DMSO, glycerol, polyethylene glycol, propylene glycol, glycerin, polyvinylpyrrolidone, sorbitol, dextran, trehalose, etc. The concentration of the cryoprotectant may also be appropriately determined.
[0024] The gel with embedded cells may be frozen at a temperature of -20°C or lower, for example, under liquid nitrogen, or may be frozen by directly placing the gel with embedded cells in a freezer at -80°C or -150°C.
[0025] The cryogelating agent of the present invention can be frozen and stored in a freezer or the like. The cryogelating agent of the present invention can be transported in a frozen state to medical institutions, dental clinics, etc. Since the agent of the present invention is frozen, it is easy to transport.
[0026] The frozen gelling preparation of the present invention is thawed at the time of use. Thawing may be performed by adding the gel to a thawing liquid and heating, or by adding a thawing liquid to the gel. Alternatively, the frozen vial containing the gel may be heated. The thawing liquid preferably contains a cell-protecting component such as a cryoprotectant or an isotonic electrolyte. The thawing conditions, such as the components in the thawing liquid, the thawing temperature, and the thawing time, can be appropriately selected depending on the size of the gel, the type of gel material, the type of cells, the number of cells, etc. As the thawing liquid, commercially available physiological saline, Cellstore (登録商標) S, Cell Store (登録商標) W, Lactec (登録商標) The thawing temperature may be, for example, 4° C. to 37° C. In general, it is better to raise the temperature quickly.
[0027] No special equipment such as a centrifuge is required when thawing and washing the frozen gelling preparation of the present invention. After thawing, the frozen gelling preparation of the present invention can be transplanted or applied as is. No special procedure is required when transplanting or applying the gelling preparation. The presence of the gel makes it easier to adhere and fix to tissue. The frozen gelling preparation of the present invention may be transplanted or applied by, for example, directly applying or embedding the preparation in tissue exposed by surgery, or may be delivered to the target tissue by injection. The frozen gelling preparation of the present invention may be transplanted or applied once or multiple times.
[0028] The cryogelation preparation of the present invention may be used for tissue healing. Tissue healing refers to returning tissue to a normal state or to a state close to the normal state, and includes tissue protection, repair of tissue / cell damage, promotion of proliferation of cells constituting the tissue, suppression of tissue inflammation, wound healing, reconstruction of tissue shape, etc.
[0029] The tissues that can be healed by the frozen gelling formulation of the present invention are any animal tissues, and are not particularly limited thereto. Examples of tissues include, but are not limited to, periodontal tissue, liver, pancreas, kidney, muscle, bone, cartilage, bone marrow, stomach, intestine, nerve, skin, mucous membrane, heart, hair, etc.
[0030] The cryogelling preparation of the present invention may be used for dental purposes. The cryogelling preparation of the present invention can be used to regenerate periodontal tissues such as gingiva, cementum, periodontal ligament, and alveolar bone.
[0031] In another aspect, the present invention provides a method for producing a frozen gelling agent, comprising embedding mesenchymal cells in a gel and freezing the gel.
[0032] The present invention will be described in more detail and specifically with reference to the following examples, but the scope of the present invention is not limited to these examples. The terms used in this specification are interpreted as they are commonly understood in the fields of medicine, pharmacology, biology, biochemistry, etc. EXAMPLES
[0033] The thawing solution used for thawing the frozen gelation preparation of the present invention was examined. Stem cells (ADMSCs) were obtained from human adipose tissue, embedded in fibrin gel, and frozen to prepare a frozen gel preparation. The specific procedure was as follows: Isolation and culture of ADMSCs Adipose tissue was minced and then digested in Hank's Buffered Salt Solution (HBSS) containing 0.008% Liberace (Roch Lifescience) for 1 hour with shaking in a water bath at 37°C. The digestion product was filtered through a Cell Strainer (BD Bioscience) and centrifuged at 800xg for 10 minutes. Red blood cells were removed by density method using lymphocyte separation solution (d=1.077) (Nacalai tesque), and the resulting cell population containing ADMSCs was seeded in DMEM containing 10% fetal bovine serum (Hyclone) to allow the cells to adhere, then washed and treated with EDTA to obtain ADMSCs. Next, the ADMSCs were seeded onto human fibronectin-coated dishes in culture medium (60% DMEM-low glucose, 40% MCDB201, 10 μg / mL EGF, 1 nM dexamethasone, 100 μM ascorbic acid, and 5% FBS) and passaged 3 to 8 times to obtain cultured ADMSCs. -Preparation of frozen gel preparations Cultured ADMSCs from passages 3 to 8 were detached using a detachment solution and suspended in a cell suspension. Beriplast P was added to the cell suspension, and after confirming that it had gelled, the cells were frozen in a -80°C freezer and then transferred to a -150°C freezer after 7 days. Each thawing solution (listed in Table 1, warmed to 37°C) was placed in a cryotube, and the frozen gelling preparation was added thereto and thawed, followed by culturing in the above medium for 24 hours. The lactic acid levels in the culture medium were measured at the start of culturing and after 24 hours of culturing. The results are shown in Table 1. The lactic acid levels at the start of culturing were all 1.6 mmol / L. [Table 1] Regardless of which thawing solution was used, a similar increase in lactate levels was observed, confirming the survival of the cells after thawing. EXAMPLES
[0034] After thawing the cryogelled preparations of the present invention in which activated or non-activated ADMSCs were embedded, the osteogenic differentiation potential of the cells was examined. IL-1β-activated or non-activated ADMSCs were embedded in fibrin gel and frozen to create a cryogel preparation. ADMSCs were obtained according to the method described in Example 1. The specific procedure for activating ADMSCs is as follows: IL-1β was added to the medium (60% DMEM-low glucose, 40% MCDB201, 10 μg / mL EGF, 1 nM dexamethasone, 100 μM ascorbic acid, and 5% FBS) to a concentration of 10 ng / ml. The cultured ADMSCs obtained in 2 above were cultured in the above IL-1β-containing medium for 72 hours, and adiponectin and hepatocyte growth factor (HGF) produced in the medium were measured. Adiponectin was measured using an ELISA kit from Abcam (catalog number ab99968). HGF was measured using an ELISA kit from R&D System (catalog number DHG00). In the control system, ADMSCs were cultured in the above medium without the addition of IL-1β. The frozen gel preparation was prepared according to the method described in Example 1. After washing and thawing the frozen gel preparation with physiological saline, additional bone differentiation culture was performed in bone differentiation medium for 14 days, and alizarin red staining was performed. The results are shown in Figure 1. Both ADMSCs activated with IL-1β and those that were not activated underwent bone differentiation after thawing. The bone differentiation ability was higher when ADMSCs activated with IL-1β were used. EXAMPLES
[0035] Using a beagle dog two-wall bone defect model (number of individuals = 5), a frozen gelation preparation was prepared by embedding ADMSCs activated with IL-1β or non-activated ADMSCs, and after thawing, the gelation preparation was transplanted into the defect. Acquisition and activation of ADMSCs, and production of the frozen gelation preparation were performed according to the method described in Example 1. Six weeks after transplantation, CT images of the transplanted area were taken and the amount of bone regeneration was calculated.The transplanted area was then sectioned and stained for histological analysis. Examples of CT images are shown in Figure 2, the calculation results of bone regeneration are shown in Figure 3, and an example of the results of histological examination is shown in Figure 4. An increase in new bone mass was confirmed in all individuals, whether non-activated or activated ADMSCs were used. New bone mass was greater when activated ADMSCs were used. Histological examination also confirmed an increase in alveolar bone and regeneration of the periodontal ligament. EXAMPLES
[0036] Cells in the frozen gelation preparation of the present invention (referred to as cell A) and cells frozen, thawed, and embedded in a gel by conventional methods (referred to as cell B) were cultured, and gene expression was examined over time. 1. Experimental Method Cell A: ADMSCs were activated with IL-1β according to the method described in Example 2. A frozen gel preparation was prepared using the activated ADMSCs according to the method described in Example 1. The frozen gel preparation was thawed and cultured while embedded in the gel. Specifically, the gel was suspended in 1 ml of medium in a well of a 24-well plate and cultured. The medium was the same as that used for the passage in Example 1. Sampling was performed at 24 hours, 48 hours, 72 hours, and 96 hours after culture, and gene expression of the cells was examined. Cell B: ADMSCs were activated with IL-1β according to the method described in Example 2. The activated ADMSCs were frozen, then thawed, embedded in a gel (Beriplast P), and cultured under the same conditions as cell A. Sampling was performed at 24 hours, 48 hours, 72 hours, and 96 hours after culture, and the gene expression of the cells was examined. Gene expression was examined by the following procedure. The cells were added with 600μL of RLT Buffer, recovered, and RNA was extracted. For the RLT Buffer sample, total RNA was extracted using RNeasy Mini Kit / QIAGEN, and total RNA was adjusted to 100ng / μL, and then labeled cRNA was synthesized from 150ng of total RNA per array. The concentration, yield, and Cy3 incorporation rate of the synthesized labeled cRNA were calculated, and the synthesis size (200-2000nt amplified) was measured. 600ng of labeled cRNA was fragmented at 60℃, hybridized at 65℃ for 17 hours, and the array was washed and scanned. 2. Experimental Results The results are shown in Figure 5. The horizontal axis represents the amount of mRNA expression in cell A, and the vertical axis represents the amount of mRNA expression in cell B. Surprisingly, gene expression in cell A correlated with gene expression in cell B, and no difference over time was observed. From the above results, it is believed that the gelling preparation of the present invention can be used in the same way as conventional transplant cells, maintains its therapeutic effect for a long period after transplantation, and does not show inappropriate gene expression. EXAMPLES
[0037] The expression of CSF2, CSF3, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, and IL-1β genes, which are thought to be important for tissue healing, was examined in cell A and cell B. The experiment was carried out according to the method described in Example 4. Figure 6 shows the expression of the above eight genes in cells A and B after 96 hours of culture. The horizontal axis shows the amount of mRNA expression in cell A, and the vertical axis shows the amount of mRNA expression in cell B. The gene expression in cell A correlated with the gene expression in cell B even after a long period of culture (96 hours), and no difference was observed. Furthermore, the expression of these eight genes in cell A at 24 hours and 96 hours after culture was examined. The experiment was carried out according to the method described in Example 4. The results are shown in Figure 7. The horizontal axis shows the amount of mRNA expression in cell A cultured for 24 hours, and the vertical axis shows the amount of mRNA expression in cell A cultured for 96 hours. Gene expression after 24 hours of culture and after 96 hours of culture showed a correlation, and no difference over time was observed. From the above results, it is believed that the frozen gelation preparation of the present invention, like conventional transplant cells, expresses genes important for tissue healing and maintains the tissue healing effect for a long period of time after transplantation. [Industrial Applicability]
[0038] The present invention is useful in the fields of tissue healing preparations, transplant preparations, dental preparations, and the like.
Claims
1. A frozen gel preparation comprising mesenchymal cells.
2. The frozen gelation preparation according to claim 1, wherein the mesenchymal cells are derived from adipose tissue.
3. The frozen gelation preparation according to claim 1, wherein the mesenchymal cells are derived from pluripotent stem cells.
4. The frozen gelation preparation according to claim 1, wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs), adipose tissue-derived cells (ASCs), bone marrow-derived stem cells (BSCs), umbilical cord-derived stem cells, dental pulp-derived stem cells, placenta-derived stem cells, cartilage-derived stem cells, or pluripotent stem cell-derived mesenchymal stem cells.
5. The frozen gelation preparation according to claim 1, wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs).
6. The frozen gelation preparation according to claim 1, wherein the mesenchymal cells are activated.
7. The cryogel preparation according to any one of claims 1 to 6, which is for tissue healing.
8. The cryogelling preparation according to any one of claims 1 to 6, which is for dental use.
9. A method for producing a frozen gelling agent, comprising embedding mesenchymal cells in a gel and freezing the gel.
10. The method according to claim 9, wherein the mesenchymal cells are derived from adipose tissue.
11. The method according to claim 9 , wherein the mesenchymal cells are derived from pluripotent stem cells.
12. The method of claim 9, wherein the mesenchymal cells are adipose tissue-derived stem cells (ADMSCs), adipose tissue-derived cells (ASCs), bone marrow-derived stem cells (BSCs), umbilical cord-derived stem cells, dental pulp-derived stem cells, placenta-derived stem cells, cartilage-derived stem cells, or pluripotent stem cell-derived mesenchymal stem cells.
13. The method of claim 9, wherein the mesenchymal cells are ADMSCs.
14. The method according to any one of claims 9 to 13, wherein the mesenchymal cells are activated.
Citation Information
Patent Citations
Method for cryopreservation of cell, cell thawing method, and cell
JP2016073207A
